AMP 579

Drug Profile

AMP 579

Alternative Names: RPR 100579

Latest Information Update: 11 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis
  • Class Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Adenosine A1 receptor agonists; Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 20 Nov 2002 Data presented at the 75th Scientific Sessions of the American Heart Association (AHA-2002) have been added to the Ischaemic Heart Disease pharmacodynamics section
  • 10 May 2000 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 10 May 2000 A study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top